Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors

Darren W. Davis, Yu Shen, Nizar A. Mullani, Sijin Wen, Roy S. Herbst, Michael O'Reilly, James L. Abbruzzese, David McConkey

Research output: Contribution to journalArticle

Abstract

Purpose: In a recent study, we presented preliminary evidence for biological activity in a Phase I dose-finding study (15-600 mg/m2) of recombinant human endostatin in patients with refractory solid tumors. Here, we conducted additional biomarker analyses to correlate changes in tumor biology with dose. Experimental Design: Excisional tumor biopsies were obtained at baseline and after 56 days of endostatin therapy. Laser scanning cytometry (LSC) was used to quantify biomarker levels in whole tissue sections. Apoptosis in tumor cells (TCs) and tumor-associated endothelial cells (ECs) was quantified by fluorescent three-color anti-CD31/terminal deoxynucleotidyl transferase-mediated nick end labeling staining. Microvessel densities were measured by LSC-guided vessel contouring. Levels of tumor-associated EC BCL-2 and hypoxia-inducible factor 1α were determined by immunofluorescence and LSC quantification. The results, including tumor blood flow measured by positron emission tomography, were analyzed using a quadratic polynomial model. Results: Significant increases in EC death and decreases in tumor microvessel density were observed, with maximal effects of endostatin at a dose of 249 mg/m2 (95% confidence interval, 159-338) and 257 mg/m2 (95% confidence interval, 183-331), respectively. In contrast, levels of TC death were uniformly low and did not correlate with endostatin dose. Maximal nuclear hypoxia-inducible factor 1α and minimal EC Bcl-2 levels were observed at ∼250 mg/m2, although the changes did not reach statistical significance. Conclusions: The data suggest that endostatin had optimal biological activity at doses ∼250 mg/m2 in our cohort of patients. Endostatin's failure to induce high levels of TC death may explain its lack of significant clinical activity in this Phase I trial.

Original languageEnglish (US)
Pages (from-to)33-42
Number of pages10
JournalClinical Cancer Research
Volume10
Issue number1 I
DOIs
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Endostatins
Biomarkers
Laser Scanning Cytometry
Neoplasms
Endothelial Cells
Hypoxia-Inducible Factor 1
Cell Death
Microvessels
Confidence Intervals
DNA Nucleotidylexotransferase
Statistical Models
Positron-Emission Tomography
Fluorescent Antibody Technique
Research Design
Color

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors. / Davis, Darren W.; Shen, Yu; Mullani, Nizar A.; Wen, Sijin; Herbst, Roy S.; O'Reilly, Michael; Abbruzzese, James L.; McConkey, David.

In: Clinical Cancer Research, Vol. 10, No. 1 I, 01.01.2004, p. 33-42.

Research output: Contribution to journalArticle

Davis, Darren W. ; Shen, Yu ; Mullani, Nizar A. ; Wen, Sijin ; Herbst, Roy S. ; O'Reilly, Michael ; Abbruzzese, James L. ; McConkey, David. / Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 1 I. pp. 33-42.
@article{fe64a892b1754791b51e7623ae34a8a2,
title = "Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors",
abstract = "Purpose: In a recent study, we presented preliminary evidence for biological activity in a Phase I dose-finding study (15-600 mg/m2) of recombinant human endostatin in patients with refractory solid tumors. Here, we conducted additional biomarker analyses to correlate changes in tumor biology with dose. Experimental Design: Excisional tumor biopsies were obtained at baseline and after 56 days of endostatin therapy. Laser scanning cytometry (LSC) was used to quantify biomarker levels in whole tissue sections. Apoptosis in tumor cells (TCs) and tumor-associated endothelial cells (ECs) was quantified by fluorescent three-color anti-CD31/terminal deoxynucleotidyl transferase-mediated nick end labeling staining. Microvessel densities were measured by LSC-guided vessel contouring. Levels of tumor-associated EC BCL-2 and hypoxia-inducible factor 1α were determined by immunofluorescence and LSC quantification. The results, including tumor blood flow measured by positron emission tomography, were analyzed using a quadratic polynomial model. Results: Significant increases in EC death and decreases in tumor microvessel density were observed, with maximal effects of endostatin at a dose of 249 mg/m2 (95{\%} confidence interval, 159-338) and 257 mg/m2 (95{\%} confidence interval, 183-331), respectively. In contrast, levels of TC death were uniformly low and did not correlate with endostatin dose. Maximal nuclear hypoxia-inducible factor 1α and minimal EC Bcl-2 levels were observed at ∼250 mg/m2, although the changes did not reach statistical significance. Conclusions: The data suggest that endostatin had optimal biological activity at doses ∼250 mg/m2 in our cohort of patients. Endostatin's failure to induce high levels of TC death may explain its lack of significant clinical activity in this Phase I trial.",
author = "Davis, {Darren W.} and Yu Shen and Mullani, {Nizar A.} and Sijin Wen and Herbst, {Roy S.} and Michael O'Reilly and Abbruzzese, {James L.} and David McConkey",
year = "2004",
month = "1",
day = "1",
doi = "10.1158/1078-0432.CCR-0736-3",
language = "English (US)",
volume = "10",
pages = "33--42",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1 I",

}

TY - JOUR

T1 - Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors

AU - Davis, Darren W.

AU - Shen, Yu

AU - Mullani, Nizar A.

AU - Wen, Sijin

AU - Herbst, Roy S.

AU - O'Reilly, Michael

AU - Abbruzzese, James L.

AU - McConkey, David

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Purpose: In a recent study, we presented preliminary evidence for biological activity in a Phase I dose-finding study (15-600 mg/m2) of recombinant human endostatin in patients with refractory solid tumors. Here, we conducted additional biomarker analyses to correlate changes in tumor biology with dose. Experimental Design: Excisional tumor biopsies were obtained at baseline and after 56 days of endostatin therapy. Laser scanning cytometry (LSC) was used to quantify biomarker levels in whole tissue sections. Apoptosis in tumor cells (TCs) and tumor-associated endothelial cells (ECs) was quantified by fluorescent three-color anti-CD31/terminal deoxynucleotidyl transferase-mediated nick end labeling staining. Microvessel densities were measured by LSC-guided vessel contouring. Levels of tumor-associated EC BCL-2 and hypoxia-inducible factor 1α were determined by immunofluorescence and LSC quantification. The results, including tumor blood flow measured by positron emission tomography, were analyzed using a quadratic polynomial model. Results: Significant increases in EC death and decreases in tumor microvessel density were observed, with maximal effects of endostatin at a dose of 249 mg/m2 (95% confidence interval, 159-338) and 257 mg/m2 (95% confidence interval, 183-331), respectively. In contrast, levels of TC death were uniformly low and did not correlate with endostatin dose. Maximal nuclear hypoxia-inducible factor 1α and minimal EC Bcl-2 levels were observed at ∼250 mg/m2, although the changes did not reach statistical significance. Conclusions: The data suggest that endostatin had optimal biological activity at doses ∼250 mg/m2 in our cohort of patients. Endostatin's failure to induce high levels of TC death may explain its lack of significant clinical activity in this Phase I trial.

AB - Purpose: In a recent study, we presented preliminary evidence for biological activity in a Phase I dose-finding study (15-600 mg/m2) of recombinant human endostatin in patients with refractory solid tumors. Here, we conducted additional biomarker analyses to correlate changes in tumor biology with dose. Experimental Design: Excisional tumor biopsies were obtained at baseline and after 56 days of endostatin therapy. Laser scanning cytometry (LSC) was used to quantify biomarker levels in whole tissue sections. Apoptosis in tumor cells (TCs) and tumor-associated endothelial cells (ECs) was quantified by fluorescent three-color anti-CD31/terminal deoxynucleotidyl transferase-mediated nick end labeling staining. Microvessel densities were measured by LSC-guided vessel contouring. Levels of tumor-associated EC BCL-2 and hypoxia-inducible factor 1α were determined by immunofluorescence and LSC quantification. The results, including tumor blood flow measured by positron emission tomography, were analyzed using a quadratic polynomial model. Results: Significant increases in EC death and decreases in tumor microvessel density were observed, with maximal effects of endostatin at a dose of 249 mg/m2 (95% confidence interval, 159-338) and 257 mg/m2 (95% confidence interval, 183-331), respectively. In contrast, levels of TC death were uniformly low and did not correlate with endostatin dose. Maximal nuclear hypoxia-inducible factor 1α and minimal EC Bcl-2 levels were observed at ∼250 mg/m2, although the changes did not reach statistical significance. Conclusions: The data suggest that endostatin had optimal biological activity at doses ∼250 mg/m2 in our cohort of patients. Endostatin's failure to induce high levels of TC death may explain its lack of significant clinical activity in this Phase I trial.

UR - http://www.scopus.com/inward/record.url?scp=1642494792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642494792&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-0736-3

DO - 10.1158/1078-0432.CCR-0736-3

M3 - Article

C2 - 14734449

AN - SCOPUS:1642494792

VL - 10

SP - 33

EP - 42

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1 I

ER -